Sanofi has secured a significant expansion of its U.S. Food and Drug Administration (FDA) approval for Tzield (teplizumab-mzwv), a groundbreaking…
Read More
Idvynso Secures FDA Approval, Charting a New Course in HIV Treatment While Biktarvy Maintains Market Dominance
MSD (Merck & Co) has achieved a significant milestone in the fight against Human Immunodeficiency Virus (HIV) with the U.S.…
Read More
The Evolving Landscape of Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment Presents New Avenues for Innovation
The treatment paradigm for locally advanced head and neck squamous cell carcinoma (LA HNSCC) is undergoing a significant transformation, driven…
Read More
US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…
Read More
Ray Therapeutics Secures $125 Million Series B Funding to Accelerate Vision Restoration Pipeline
Ray Therapeutics, a biopharmaceutical company at the forefront of developing novel gene therapies for vision restoration, has successfully closed a…
Read More
The Alarming Rise of Unregulated Weight Loss Medications in the UK: A Public Health Crisis in the Making
British people are increasingly turning to potentially unregulated weight loss medications as drug prices climb and waits for prescriptions lengthen.…
Read More
Asahi Kasei acquires German company Aicuris
TOKYO, JAPAN – Asahi Kasei, a diversified Japanese chemical company with a significant and growing presence in healthcare, has officially…
Read More
Pfizer and Astellas Secure FDA Priority Review for Perioperative Padcev and Keytruda Combination in Muscle-Invasive Bladder Cancer
The United States Food and Drug Administration (FDA) has granted priority review to a supplemental biologics license application (sBLA) from…
Read More
Eli Lilly Expands In Vivo Gene Therapy Arsenal with $7 Billion Acquisition of Kelonia Therapeutics
Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with…
Read More
UCB Acquires Neurona Therapeutics for Up to $1.15 Billion to Bolster Epilepsy Pipeline with Regenerative Cell Therapy
BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read MoreYOU MAY HAVE MISSED
